Company Overview and News

8
Portfolio picks: These 5 stocks can be multibaggers in the next 2-3 years

2018-06-20 moneycontrol
Soumen Chatterjee, Director Research, Guiness Securities, expects one more rate hike in the latter half of the year, given the surge in oil prices. “If the monsoon remains normal as predicted by the India Meteorological Department, we will see a dovish stance from the Monetary Policy Committee accompanied by a 25 bps rate hike later in the year.”
ICICIBANK 532540 NATCOPHARM 532174 IBN 524816 TCS HEXAWARE 532129 TTNQY

21
Market Live: Sell-off continues on trade tensions; all sectoral indices in the red

2018-06-19 moneycontrol
Oil Prices Update: Oil prices fell nearly one percent as an escalating trade dispute between the United States and China triggered sharp selloffs in many global markets.
LIBERTSHOE 523768 500325 GOACARBON GUJBOROS RELIANCE GLKQY 539437 500470 IDFCBANK RIGD 500790 NSZTY RLNIY 509567 SBAZ GLENMARK IBN 502219 TATAPOWER NESTLEIND HEXAWARE 539302 532129 POWERMECH BOROSIL ICICIBANK TTST 532296 TATASTEEL TATLY 532174 TPCL 500400 526596

36
Market Live: Sensex extends losses amid trade war woes; IOC, HPCL, BPCL dip 3%

2018-06-19 moneycontrol
Glenmark Pharmaceuticals announced that the US Food & Drug Administration provided its first supplemental abbreviated new drug application (sANDA) approval for the company’s manufacturing facility in Monroe, North Carolina.
LIBERTSHOE 523768 500325 GUJBOROS RELIANCE KAJARIACER 532418 BHRQY GLKQY 532215 JUSTDIAL CMQMY 500470 535648 533407 AXISBANK RIGD 500233 CUMMINSIND BHARTIARTL 500790 NSZTY RLNIY SBAZ GLENMARK AXB 502219 IBN NESTLEIND HEXAWARE 539302 532129 AXBKY POWERMECH 532454 BOROSIL AXBA 500480 ICICIBANK TTST 532296 TATASTEEL TATLY 532174 CNOVAPETRO 526596 JSTQY ANDHRABANK

0
Acko Insurance raises $12 million from Amazon, Ashish Dhawan of ChrysCapital

2018-05-28 moneycontrol
Non-life insurance company Acko General Insurance on Monday said that it has raised a new round of investment of USD 12 million led by e-commerce giant Amazon.
HEXAWARE 532129

0
Hexaware Technologies Limited - Updates

2018-05-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HEXAWARE 532129

0
IT stocks in focus: Infosys, TCS surge up to 3 pc

2018-05-25 moneycontrol
IT stocks were in limelight today, rising up to 3 percent, on weak rupee that hit a near 18-month low yesterday, a trend which is largely seen as positive for export-focussed sectors. Shares of Infosys rose by 3.09 percent, TCS 3.08 percent, HCL Technologies 1.86 percent, Hexaware Technologies 1.85 percent, Tech Mahindra 1.75 percent and Wipro 0.36 percent on the BSE.
HCLTECH HCTHY 532281 TCHQY HEXAWARE 532129 532755 TECHM

0
Hexaware Technologies Limited - Reply to Clarification- Financial results

2018-05-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HEXAWARE 532129

0
Hexaware Technologies Limited - Clarification - Financial Results

2018-05-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HEXAWARE 532129

0
Hexaware Technologies Limited - Press Release

2018-05-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HEXAWARE 532129

37
Sensex loses 261 pts in 2 straight sessions after hitting 3-month high; PC Jeweller up 44%

2018-05-04 moneycontrol
Profit booking and weak Asian cues pulled the market lower for the second consecutive session today after hitting a three-month high Wednesday. ITC, Reliance Industries, Infosys and select banking and financials stocks led the market down.
BAJAJ-AUTO 500325 HCMLY 500425 533150 RELIANCE TCHQY 532977 BHRQY AMBUJACEM 532755 532215 505200 532541 AMBUY AXISBANK RIGD HDFCBANK BHARTIARTL EICHERMOT RLNIY NIITTECH YESBANK ECQRY AXB IBN 532648 YYBKY HEXAWARE 532129 TECHM AXBKY 532454 AXBA ICICIBANK GODREJPROP HCMLF HDB 532174 500180 534809 PCJEWELLER

0
Hexaware Technologies Limited - Shareholders meeting

2018-05-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HEXAWARE 532129

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...